Sign the Petition- HCV research funding conflicts of interests at NIH
Download - Printer Friendly Version
 

Contact:
NIH Directors
Institute and Center leaders

Mailing Addresses
for NIH Institutes and Centers

HCV Research

Track Funding

HCV Funded Studies:

HCV Research

HIV Research

Hepatitis B & Viral Hepatitis" Studies

Liver Disease Research

Unknown Category Research

Charts & Data

Treatments

Clinical Trials

Cirrhosis, HCC & Transplant Research

Mental Health

Harm Reduction

Snapshot NIH-TransPlan for HCV Funding

 

 

PRESS RELEASE:
Millions of  Dollars Redirected HepCop has publicly denounced the National Institutes of Health (NIH) for spending millions of dollars budgeted for Hepatitis C (HCV) on other research agendas.

HCV Treatment Research Funding
Grants Project Number Researcher Cost Project Title
NCI 3R21CA125321-02S1 SNYDER, NED $20,868  Variation in NTP use by the HCV polymerase and response to therapy
5R21CA125321-02 SNYDER, NED $147,000  Variation in NTP use by the HCV polymerase and response to therapy
NCRR 5M01RR000051-47 FAN, XIAOFENG $17,798  HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)

$88,871

5P51RR013986-10 LAUER, GEORG $3,870  EVALUATION OF ANTIVIRALS FOR HEPATITIS C VIRUS IN CHIMPANZEES
5P51RR013986-10 LAUER, GEORG $1,015  HCV ANTIVIRAL TESTING IN CHIMPANZEES
5P51RR013986-10 LAUER, GEORG $381  HCV ANTIVIRAL TESTING IN CHIMPANZEES
5M01RR000073-45 SCHACKMAN, BRUCE $667  A PILOT STUDY TO CHARACTERIZE INTERFERON-INDUCED GENE EXPRESSION IN LIVER CELLS
5P51RR013986-10 LAUER, GEORG $698  HCV ANTIVIRAL TESTING IN CHIMPANZEES
5M01RR020359-04 MOHAN, PARVATHI $61,609  PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV
5M01RR001346-27 SCHWARZ, KATHLEEN $289  REDUCING DEPRESSIVE SYMPTOMS DURING HCV THERAPY: A RANDOMIZED STUDY
5M01RR000750-36 MOLLESTON, JEAN $2,544  PEGINTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV
NHLBI 5R01HL073921-05 MILLER, ANDREW $290,143  Pathophysiology of IFN-alpha-induced Sleep Disturbances
NIAAA 5U19AI040034-14 HAHN, YOUNG $30,244  Global Transcriptional Responses in IFN Therapy for HCV
NIAID 5K08AI069989-02 WANG, XIN $105,570  An in vitro system to study antiviral strategies against Hepatitis C virus
$1,605,509 1R43AI074214-01A1 KAMAL, SANAA $295,743  An RNAi Trojan Horse for treatment of hepatitis C.
5R01AI065256-03 RODRIGUES, LIA $686,648  Antiretroviral Therapy and the Hepatitis C Virus
1R43AI078638-01A1 MORCOL, TULIN $142,250  Calcium phosphate-interferon (CaP-IFN) particles for pulmonary delivery of IFN
1F31AI071353-01A2 EL-BASSEL, NABILA $31,852  Type I Interferon Responses to Hepatitis C Virus
5U19AI040034-14 HAHN, YOUNG $219,246  Global Transcriptional Responses in IFN Therapy for HCV
5K23AI065630-04 JOHNSON, RAY $124,200  Molecular Basis of Interferon Response in HCV
NIDDK 5R01DK071560-04 RITOLA, KIMBERLY $270,459  Innate Immune Responses During Therapy for Chronic HCV
$1,506,950 3U01DK067767-05S1 REHERMANN, BARBARA $500,000  Pegylated Interferon +/- Ribavirin for Children with HCV
5F32DK080650-02 REHERMANN, BARBARA $51,278  Viral Dynamics of HCV Serine Protease Inhibitor Resistance
1Z01DK054505-12 LINAS, BENJAMIN $503,301  Mechanisms of Interferon Action and Resistance in Hepatitis C Virus Infection
5R21DK078100-02 JACOB, SAMSON $181,912  Ribavirin Pharmacokinetics, Race and HCV Treatment
NIMH 5R01MH067990-05 MILLER, ANDREW $261,130  Fronto-Striatal Dysfunction in IFNa-Induced Depression
$587,542 5R01MH070553-04 RADZIEWICZ, HENRY $326,412  Cytokine-CRH Interactions in IFN-alfa-Induced Depression
       
HCV Treatment Funding $4,277,127  

HIV/HCV Treatment Research Funding
Grants Project Number Researcher Cost Project Title
NCRR 5M01RR000051-47 CAMPBELL, THOMAS $14,142  SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV & HIV-1 COINFECTED SUBJECTS (SLAM-C)
$59,181 5M01RR000865-35 MOE, ARDIS $31,623  SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV
5M01RR000750-36 KALAMS, SPYROS $6,133  SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV
2M01RR000046-48 WAGNER, GLENN $7,283  LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS (SLAM-C)
NIAID 5R37AI028731-19 LITWIN, ALAIN $324,651  Noncarbohydrate Approaches to AntiAIDS Nuleosides
  1R43AI075829-01A1 EL-SERAG, HASHEM $300,000 Generation of novel HCV drugs through engineereing of the cssA gene
$3,128,373 1R01AI073219-01A2 MONTANER, LUIS $632,784  NK/DC Cross-Talk and Antiviral Response
1Z01AI001016-02 PTACEK, JENNIFER $690,432  New Approaches To Passive Immunoprophylaxis
1Z01AI000823-11 PTACEK, JENNIFER $836,285  New Approaches To Active Immunoprophylaxis
5K01AI073193-02 LINDBLAD, ANNE $135,815  Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs
2R01AI052065-05A2 KULIG, CLARK $533,057  HCV and HIV Progression in Women on HAART
NIDA 1K01DA024654-01 PFEFFER, LAWRENCE $180,360  Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients
NIDDK 2R01DK063222-05A2 HASSAN, MANAL $257,550  Role of NK in Regulation of anti-viral T cell immunity
NIMH 1R01MH083553-01A1 HOSMANE, RAMACHANDRA $605,589  Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy
$992,488 1R21MH078740-01A2 SUN, JIAREN $238,108  Enhancing HCV Treatment Decisions in HIV Co-Infected Patients and Their Providers
5K23MH071177-04 THOMAS, DAVID $148,791  Adherence to HCV Treatment in HCV and HCV/HIV Patients
       
 

HCV Research Funding for
HIV Treatment

$4,942,603  


Other THAN HCV Treatment Research Funding

Grants Project Number Name Cost Project Title
NCCAM 1R21AT002895-01A2 PILLAI, SATISH $247,685 Mechanisms of Action of Silymarin for Hepatitis C
NCRR 5P41RR001209-29 BUSSIERE, DIRKSEN $184 STRUCTURAL STUDIES ON KEY DRUG TARGETS: HUMAN KINASES AND NTP-BINDING PROTEINS
  5M01RR001032-33 LAW, MANSUN $5,699 RACIAL DIFFERENCES IN IFN TRANSCRIPTIONAL RESPONSE
NHLBI 5U01AI063589-05 RITOLA, KIMBERLY $472,639 Molecular profiling and immunomodulatory interventions
NIAID 5U01AI063589-05 RITOLA, KIMBERLY $2,244,524 Molecular profiling and immunomodulatory interventions
  5R21AI077018-02 SMITH, RICHARD $288,701 The novel chromatin-based mechanism of antiviral resistance
  1R01DA024555-01A1 LETENDRE, SCOTT $378,064 Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site
  1R01DA024554-01A1 NORTH, CAROL $380,536 Treatment Studies Using Depot Naltrexone (4/6) Columbia Protocol Treatment Site
  1R01DA024553-01A1 NUNES, EDWARD $591,774 Treatment Study Using Depot Naltrexone(1/6)Philadelphia Coord/Data Mgmt Site
  1R01DA024550-01A1 KOZIEL, MARGARET $309,076 Treatment Study Using Depot Naltrexone(5/6)Baltimore Protocol Treatment Site
  1R01DA024549-01A1 GARCIA-TSAO, GUADALUPE $355,583 Treatment Study Using Depot Naltrexone(2/6)Rhode Island Protocol Treatment Site
NIDDK 5R01DK068598-04 LAW, MANSUN $373,299 Racial Differences in IFN Transcriptional Response
  1Z01DK054508-11 RAY, STUART $289,923 Analysis and Modulation of Virus-Host Interaction in Animal Models
  1Z01DK031128-02 JHAVERI, RAVI $200,250 Development of Nucleoside Derivatives for Nonreceptor Targets
 
   

Total
$6,137,937
 


 


 

Source: National Institutes of Health Research Portfolio Online Reporting Tool (RePORT) Reports,
Data and Analyses of NIH Research Activities
Retrieved on March 18, 2009
http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2008&DCat=Hepatitis+-+C

Permission is granted to use all information from this website in pursuit of ending NIH's "Trans-Plan" discriminatory practices against HCV research funding allocations. Please Credit: HCVets.com Educational Website & Support Forums for Military Related HCV Exposures.

Contact HepCop   
Email: Staff